Rumatin MR 100/325/250 mg
Aceclofenac (100mg) + Paracetamol (325mg) + Chlorzoxazone (250mg)
Rumatin MR helps relieve pain, inflammation, and muscle stiffness in arthritis, strains, and backache while supporting improved comfort and mobility with fast, effective symptomatic relief.
- Strengths 100/325/250 mg
- Form tablet
- Packaging Size
- Packaging Type Box
- Manufacturer Vivimed Labs Pvt Ltd
Description of Rumatin MR 100/325/250 mg
Rumatin MR is a combination medicine used to treat pain, swelling, and muscle spasms associated with musculoskeletal conditions. Its active ingredients work together to reduce the chemicals in the body that cause pain and inflammation while relaxing tight muscles. This makes Rumatin MR useful for conditions such as arthritis, joint pain, backache, sprains, and muscle strain. When taken exactly as prescribed by a healthcare professional, this medicine helps improve comfort and mobility by easing painful symptoms. Always follow your doctor’s instructions and do not exceed the recommended dose or duration for safe and effective use.
Ingredients of Rumatin MR 100/325/250 mg
- Aceclofenac – reduces pain and inflammation
- Paracetamol – pain reliever and fever reducer
- Chlorzoxazone – muscle relaxant that eases stiffness
Usage of Rumatin MR 100/325/250 mg
- Take Rumatin MR only as prescribed by your doctor
- Usually taken after meals to reduce stomach irritation
- Swallow with water and do not exceed the recommended dose
Precautions for Rumatin MR 100/325/250 mg
- Avoid alcohol while taking this medicine
- Use with caution if you have liver, kidney, or stomach conditions
- Consult a doctor before use during pregnancy or breastfeeding
- Long-term use should be under medical supervision
- Inform your doctor about other medicines you are taking
Product Reviews
Want to leave a review?
Please log in so we can verify your purchase and keep reviews genuine.
More like this
Find related medicines from trusted suppliers. Explore similar products to ensure you get the right medication for your needs.
